journal
MENU ▼
Read by QxMD icon Read
search

Bone Marrow Transplantation

journal
https://www.readbyqxmd.com/read/28920950/impact-of-a-dedicated-post-transplant-vaccination-service-at-an-australian-cancer-centre
#1
B W Teh, T Joyce, M A Slavin, K A Thursky, L J Worth
No abstract text is available yet for this article.
September 18, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28920949/autologous-hematopoietic-cell-transplantation-for-multiple-myeloma-patients-with-renal-insufficiency-a-center-for-international-blood-and-marrow-transplant-research-analysis
#2
A Mahindra, P Hari, R Fraser, M Fei, J Huang, J Berdeja, N Callander, L Costa, M A Diaz, C Freytes, R P Gale, S Girnius, L Holmberg, M Kharfan-Dabaja, S Kumar, R Kyle, H Lazarus, C Lee, A Maiolino, J Moreb, T Nishihori, A Pawarode, A Saad, B N Savani, J Schriber, B William, B M Wirk, A Krishnan, Y Nieto, A D'Souza
Autologous hematopoietic cell transplantation (AHCT) in multiple myeloma (MM) patients with renal insufficiency (RI) is controversial. Patients who underwent AHCT for MM between 2008 and 2013 were identified (N=1492) and grouped as normal/mild (⩾60 mL/min), N=1240, moderate (30-59), N=185 and severe RI (<30), N=67 based on Modification of Diet in Renal Disease. Multivariate analyses of non-relapse mortality (NRM), relapse, PFS and overall survival (OS) were performed. Of the 67 patients with severe RI, 35 were on dialysis prior to AHCT...
September 18, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28920948/rejection-of-paternal-vs-maternal-fully-matched-bone-marrow-grafts-in-children-with-thalassemia
#3
S Ramprakash, R K Agarwal, R Dhanya, A Sedai, A Kumari, L Parmar, R Srinivas, V R Kakulamari, P Marwah, R Soni, S Williams, W Rathnayake, S Sen, S Tulpule, L Faulkner
No abstract text is available yet for this article.
September 18, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28920947/the-capacity-building-approach-was-successful-in-the-start-up-process-of-the-first-hsct-center-in-iraqi-kurdistan
#4
I Majolino, A Rovelli, M Vacca, M Verna, M Canesi, V Conter, D Othman
No abstract text is available yet for this article.
September 18, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28920946/potential-niche-indications-for-blinatumomab-as-a-bridge-to-hematopoietic-cell-transplantation
#5
Yi Zeng, Emmanuel Katsanis
No abstract text is available yet for this article.
September 18, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28892087/durable-remission-with-salvage-decitabine-and-donor-lymphocyte-infusion-dli-for-relapsed-early-t-cell-precursor-all
#6
F E L Chaer, N Holtzman, E Binder, N C Porter, Z N Singh, M Koka, A P Rapoport, A Emadi
No abstract text is available yet for this article.
September 11, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28892086/allogeneic-stem-cell-transplantation-and-subsequent-treatments-as-a-comprehensive-strategy-for-long-term-survival-of-multiple-myeloma-patients
#7
V Montefusco, A Mussetti, F Rezzonico, F Maura, M Pennisi, C de Philippis, M Capecchi, P Corradini
We evaluated 71 patients treated with allogeneic hematopoietic cell transplantation (allo-HCT) for multiple myeloma (MM). Forty-three patients (61%) received allo-HCT after the first line of therapy. Fifty-eight patients (82%) had chemosensitive disease at the time of allo-HCT. A HLA-matched related or unrelated donor was available for 68 patients (96%). Non-myeloablative or reduced-intensity conditioning regimen and peripheral blood hematopoietic cells as a graft source were used in most patients. The cumulative incidence of grade II-IV acute GVHD at day +100 and chronic GVHD at 5 years was 13% (95% CI 7-23%) and 35% (95% CI 24-46), respectively...
September 11, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28892085/circulating-endothelial-cell-count-a-reliable-marker-of-endothelial-damage-in-patients-undergoing-hematopoietic-stem-cell-transplantation
#8
C Almici, C Skert, B Bruno, A Bianchetti, R Verardi, A Di Palma, A Neva, S Braga, G Piccinelli, G Piovani, M Malagola, S Bernardi, L Giaccone, L Brunello, M Festuccia, K Baeten, D Russo, M Marini
The physio-pathologic interrelationships between endothelium and GvHD have been better elucidated and have led to definition of the entity 'endothelial GvHD' as an essential early phase prior to the clinical presentation of acute GvHD. Using the CellSearch system, we analyzed circulating endothelial cells (CEC) in 90 allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients at the following time-points: T1 (pre-conditioning), T2 (pre-transplant), T3 (engraftment), T4 (onset of GvHD) and T5 (1 week after steroid treatment)...
September 11, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28892084/validation-of-the-revised-ipss-at-transplant-in-patients-with-myelodysplastic-syndrome-transformed-acute-myelogenous-leukemia-receiving-allogeneic-stem-cell-transplantation-a-retrospective-analysis-of-the-ebmt-chronic-malignancies-working-party
#9
C Scheid, L de Wreede, A van Biezen, C Koenecke, G Göhring, L Volin, J Maertens, J Finke, J Passweg, D Beelen, J J Cornelissen, M Itälä-Remes, P Chevallier, N Russell, E Petersen, N Milpied, C Richard Espiga, A Peniket, J Sierra, G Mufti, C Crawley, J H Veelken, P Ljungman, J Y Cahn, E P Alessandrino, T de Witte, M Robin, N Kröger
The International Prognostic Scoring System has been revised (IPSS-R) to predict prognosis of patients with myelodysplastic syndromes at diagnosis. To validate the use of the IPSS-R assessed before transplant rather than at diagnosis we performed a retrospective analysis of the EBMT database. A total of 579 patients had sufficient information available to calculate IPSS-R at transplant. Median overall survival (OS) from transplant was significantly different according to IPSS-R: very low 23.6 months, low 55...
September 11, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28892083/depression-and-anxiety-following-hematopoietic-stem-cell-transplantation-a-prospective-population-based-study-in-germany
#10
K Kuba, P Esser, A Mehnert, C Johansen, A Schwinn, L Schirmer, F Schulz-Kindermann, M Kruse, U Koch, A Zander, N Kröger, H Götze, A Scherwath
In this prospective multicenter study, we investigated the course of depression and anxiety during hematopoietic stem cell transplantation (HSCT) until 5 years after transplantation adjusting for medical information. Patients were consulted before HSCT (n=239), at 3 months (n=150), 12 months (n=102) and 5 years (n=45) after HSCT. Depression and anxiety were assessed with the Hospital Anxiety and Depression Scale (HADS). Detailed medical and demographic information was collected. Prevalence rates were compared with an age- and gender-matched control group drawn from a large representative sample (n=4110)...
September 11, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28869619/%C3%AE-%C3%AE-t-cell-depleted-donor-lymphocyte-infusion-for-leukemia-relapse-after-allogeneic-stem-cell-transplantation
#11
L Kordelas, U Buttkereit, M Lindemann, M Koldehoff, V Klisanin, P A Horn, K Fleischhauer, D W Beelen
No abstract text is available yet for this article.
September 4, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28869618/outcomes-following-autologous-hematopoietic-stem-cell-transplant-for-patients-with-relapsed-wilms-tumor-a-cibmtr-retrospective-analysis
#12
M H Malogolowkin, M T Hemmer, J Le-Rademacher, G A Hale, P A Metha, A R Smith, C Kitko, A Abraham, H Abdel-Azim, C Dandoy, M Angel Diaz, R P Gale, G Guilcher, R Hayashi, S Jodele, K A Kasow, M L MacMillian, M Thakar, B M Wirk, A Woolfrey, E L Thiel
Despite the marked improvement in the overall survival (OS) for patients diagnosed with Wilms' tumor (WT), the outcomes for those who experience relapse have remained disappointing. We describe the outcomes of 253 patients with relapsed WT who received high-dose chemotherapy (HDT) followed by autologous hematopoietic stem cell transplant (HCT) between 1990 and 2013, and were reported to the Center for International Blood and Marrow Transplantation Research. The 5-year estimates for event-free survival (EFS) and OS were 36% (95% confidence interval (CI); 29-43%) and 45% (95 CI; 38-51%), respectively...
September 4, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28869617/a-phase-1-trial-of-90-y-zevalin-radioimmunotherapy-with-autologous-stem-cell-transplant-for-multiple-myeloma
#13
A Dispenzieri, A D'Souza, M A Gertz, K Laumann, G Wiseman, M Q Lacy, B LaPlant, F Buadi, S R Hayman, S K Kumar, D Dingli, W J Hogan, S M Ansell, D A Gastineau, D J Inwards, I N Micallef, L F Porrata, P B Johnston, M R Litzow, T E Witzig
This phase 1 study (clinical trial NCT00477815) was conducted to determine the maximum tolerated dose (MTD) of yttrium-90 ibritumomab tiuxetan ((90)Y-Zevalin) with high dose melphalan (HDM) therapy in multiple myeloma (MM) patients undergoing autologous stem cell transplantation (ASCT). In a 3+3 trial design, 30 patients received rituximab 250 mg/m(2) with indium-111 ibritumomab tiuxetan ((111)In-Zevalin) for dosimetry (day -22); rituximab 250 mg/m(2) with escalating doses of (90)Y-Zevalin (day -14); melphalan 100 mg/m(2) (days -2,-1) followed by ASCT (day 0) and sargramostim (GM-CSF, day 0) until neutrophil engraftment...
September 4, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28869616/successful-bone-marrow-transplantation-in-two-sisters-with-activated-phosphoinositide-3-kinase-%C3%AE-syndrome-2
#14
M Sugiyama, A Iguchi, M Yamada, Y Terashita, J Ohshima, Y Cho, N Miyake, N Matsumoto, M Ueki, Y Yamazaki, S Takezaki, I Kobayashi, T Ariga
No abstract text is available yet for this article.
September 4, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28869615/acute-and-fatal-cardiotoxicity-following-high-dose-cyclophosphamide-in-a-patient-undergoing-autologous-stem-cell-transplantation-for-systemic-sclerosis-despite-satisfactory-cardiopulmonary-screening
#15
M Martin, L-M Fornecker, L Marcellin, E Mousseaux, A Hij, J A Snowden, D Farge, T Martin
No abstract text is available yet for this article.
September 4, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28869614/impact-of-cigarette-smoking-on-survival-after-myeloablative-allogeneic-hematopoietic-stem-cell-transplantation-and-contribution-of-invasive-fungal-infection
#16
A Mehdi, L Rybicki, S Mossad, M Yurch, M Sekeres, A T Gerds, D Jagadeesh, B Hamilton, H Liu, R Dean, B Pohlman, R Sobecks, S Andresen, M Kalaycio, B J Bolwell, N S Majhail, E Copelan, B T Hill
No abstract text is available yet for this article.
September 4, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28869613/age-does-not-adversely-influence-outcomes-among-patients-older-than-60-years-who-undergo-allogeneic-hematopoietic-stem-cell-transplant-for-aml-and-myelodysplastic-syndrome
#17
D Modi, A Deol, S Kim, L Ayash, A Alavi, M Ventimiglia, D Bhutani, V Ratanatharathorn, J P Uberti
Allogeneic hematopoietic stem cell transplant (AHSCT) outcomes data of older AML/myelodysplastic syndrome (MDS) patients are limited. We retrospectively evaluated consecutive patients ⩾60 years old with AML/MDS who underwent AHSCT between January 2005 and December 2014. The primary objectives were to determine nonrelapse mortality (NRM), relapse, relapse-free survival (RFS) and overall survival (OS) at 1 year post AHSCT. A total of 159 patients underwent AHSCT with a median age of 64 (range, 60-75) years...
September 4, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28825694/monozygotic-twins-with-gata2-deficiency-same-haploidentical-related-donor-different-severity-of-gvhd
#18
N N Shah, M Parta, K Baird, H Rafei, K Cole, S M Holland, D D Hickstein
No abstract text is available yet for this article.
August 21, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28825693/thrombotic-microangiopathy-associated-with-monoclonal-gammopathy-following-autologous-hematopoietic-stem-cell-transplantation-for-neuroblastoma-in-a-young-child
#19
M Henry, R P Valentini, S Savaşan
No abstract text is available yet for this article.
August 21, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28805792/immune-reconstitution-in-patients-with-acquired-severe-aplastic-anemia-after-haploidentical-stem-cell-transplantation
#20
X-Y Pei, X-Y Zhao, L-P Xu, Y Wang, X-H Zhang, Y-J Chang, X-J Huang
Immune recovery (IR) after haploidentical stem cell transplantation (haplo-SCT) in severe aplastic anemia (SAA) patients remains relatively unknown. In this study, we examined immune cell subset counts and immunoglobulins in 81 SAA patients from day 30 to day 365 after haplo-SCT. Simultaneously, we determined which factors influence IR and analyzed the effects of immune cell subsets on transplant outcomes. We found that: (i) The reconstitution of different immune cell subsets occurred at different rates after haplo-SCT...
August 14, 2017: Bone Marrow Transplantation
journal
journal
20054
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"